91勛圖厙

>

Association between genetically predicted expression of TPMT and azathioprine adverse events

Steitz, Alyssa; Daniel, Laura L.; Nepal, Puran; Dickson, Alyson L.; Zanussi, Jacy; Miller-Fleming, Tyne W.; Straub, Peter S.; Wei, Wei-Qi; Liu, Ge; Maizel, Jennifer; Cox, Nancy J.; Hung, Adriana M.; Feng, QiPing; Stein, C. Michael; Chung, Cecilia P. (2026).泭.泭BMC Pharmacology and Toxicology, 27(1), 89.泭

Some people experience serious side effects from��azathioprine, a medication commonly used to treat autoimmune diseases, and genetic differences can influence that risk. While variants in the��TPMT泭硃紳餃泭NUDT15��genes are already known to increase the likelihood of��myelotoxicity��(damage to the bone marrow that can reduce blood cell production), other genetic factors remain less well understood. In this study, the researchers used��PrediXcan, a computational method that estimates how strongly a person’s genes are likely to be expressed based on their genetic data, to investigate whether predicted gene expression was associated with known azathioprine side effects. They analyzed data from 1,364 people who had recently started azathioprine and found that individuals with the lowest predicted expression of the��TPMT��gene had more than three times the odds of developing��leukopenia��(a low white blood cell count) compared with those with the highest predicted TPMT expression. No significant associations were found for other known side effects. These findings suggest that approaches such as PrediXcan may help identify additional genetic factors that influence how people respond to medications, supporting more personalized treatment in the future.

Fig 1

Predicted expression of��TPMT��in liver tissue by��TPMT��phenotype group

Explore Story Topics